Etzer Darout
Stock Analyst at BMO Capital
(3.29)
# 980
Out of 4,732 analysts
103
Total ratings
33.77%
Success rate
7.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IGMS IGM Biosciences | Downgrades: Market Perform | $21 → $2 | $1.83 | +9.29% | 2 | Jan 10, 2025 | |
| EXEL Exelixis | Downgrades: Market Perform | $36 → $40 | $36.55 | +9.44% | 3 | Dec 20, 2024 | |
| QTTB Q32 Bio | Maintains: Outperform | $64 → $22 | $3.14 | +600.64% | 2 | Dec 12, 2024 | |
| TRML Tourmaline Bio | Initiates: Outperform | $50 | $17.33 | +188.52% | 1 | Dec 6, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Outperform | $62 | $36.54 | +69.68% | 1 | Dec 6, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Outperform | $35 | $19.49 | +79.58% | 1 | Dec 6, 2024 | |
| KYMR Kymera Therapeutics | Initiates: Market Perform | $55 | $40.29 | +36.51% | 1 | Dec 6, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $63 | $5.34 | +1,079.78% | 1 | Dec 6, 2024 | |
| ARVN Arvinas | Maintains: Outperform | $90 → $88 | $17.58 | +400.57% | 2 | Nov 20, 2024 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $28 → $27 | $5.55 | +386.49% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $75.99 | +76.34% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 → $34 | $20.03 | +69.75% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $21.22 | +126.20% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $97.86 | +22.62% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $38 | $43.90 | -13.44% | 3 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 → $26 | $4.50 | +477.78% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $25 | $6.18 | +304.53% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $5 | $3.03 | +65.02% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $3.86 | +418.13% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $91 | $39.65 | +129.51% | 5 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.25 | +380.00% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3.25 → $3.59 | $0.85 | +323.80% | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $123 → $122 | $112.76 | +8.19% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $66.91 | +22.55% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.16 | +455.56% | 2 | Sep 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $4.20 | +352.38% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $249.16 | -31.77% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $84 | $6.10 | +1,277.05% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $24.01 | +124.91% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $45.83 | -17.08% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $2.51 | +1,971.71% | 1 | Mar 28, 2018 |
IGM Biosciences
Jan 10, 2025
Downgrades: Market Perform
Price Target: $21 → $2
Current: $1.83
Upside: +9.29%
Exelixis
Dec 20, 2024
Downgrades: Market Perform
Price Target: $36 → $40
Current: $36.55
Upside: +9.44%
Q32 Bio
Dec 12, 2024
Maintains: Outperform
Price Target: $64 → $22
Current: $3.14
Upside: +600.64%
Tourmaline Bio
Dec 6, 2024
Initiates: Outperform
Price Target: $50
Current: $17.33
Upside: +188.52%
Protagonist Therapeutics
Dec 6, 2024
Initiates: Outperform
Price Target: $62
Current: $36.54
Upside: +69.68%
Nurix Therapeutics
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $19.49
Upside: +79.58%
Kymera Therapeutics
Dec 6, 2024
Initiates: Market Perform
Price Target: $55
Current: $40.29
Upside: +36.51%
Jasper Therapeutics
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $5.34
Upside: +1,079.78%
Arvinas
Nov 20, 2024
Maintains: Outperform
Price Target: $90 → $88
Current: $17.58
Upside: +400.57%
Acrivon Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $5.55
Upside: +386.49%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $75.99
Upside: +76.34%
Nov 8, 2024
Reiterates: Outperform
Price Target: $32 → $34
Current: $20.03
Upside: +69.75%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $21.22
Upside: +126.20%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $97.86
Upside: +22.62%
Oct 11, 2024
Maintains: Outperform
Price Target: $34 → $38
Current: $43.90
Upside: -13.44%
Sep 16, 2024
Reiterates: Outperform
Price Target: $19 → $26
Current: $4.50
Upside: +477.78%
Aug 13, 2024
Maintains: Outperform
Price Target: $26 → $25
Current: $6.18
Upside: +304.53%
Aug 7, 2024
Maintains: Market Perform
Price Target: $8 → $5
Current: $3.03
Upside: +65.02%
Aug 6, 2024
Reiterates: Outperform
Price Target: $20
Current: $3.86
Upside: +418.13%
Jun 4, 2024
Maintains: Outperform
Price Target: $84 → $91
Current: $39.65
Upside: +129.51%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.25
Upside: +380.00%
May 9, 2024
Maintains: Market Perform
Price Target: $3.25 → $3.59
Current: $0.85
Upside: +323.80%
May 7, 2024
Maintains: Outperform
Price Target: $123 → $122
Current: $112.76
Upside: +8.19%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $66.91
Upside: +22.55%
Sep 1, 2023
Reiterates: Buy
Price Target: $12
Current: $2.16
Upside: +455.56%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $4.20
Upside: +352.38%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $249.16
Upside: -31.77%
Jul 12, 2021
Initiates: Buy
Price Target: $84
Current: $6.10
Upside: +1,277.05%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $24.01
Upside: +124.91%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $45.83
Upside: -17.08%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $2.51
Upside: +1,971.71%